Anti-SUPT16H (aa 385-397) polyclonal antibody

Antibody Isotype

IgG

Species Reactivity

Human

Immunogen

Synthetic peptide: DLTNKEGKKPEEK with a Cysteine residue linker, corresponding to internal sequence amino acids 385-397 of Human SUPT16H

Conjugate

Application Notes

WB: 0.1 - 0.3 μg/ml; ELISA: 1/8000; IHC-P: 3.75 μg/ml.

Alternative Names

SUPT16H; suppressor of Ty 16 homolog (S. cerevisiae); suppressor of Ty (S.cerevisiae) 16 homolog; FACT complex subunit SPT16; CDC68; facilitates chromatin remodeling 140 kDa subunit; FACT; FACTP140; FLJ10857; FLJ14010; SPT16/CDC68; hSPT16; FACT 140 kDa su

Entrez Gene ID

UniProt ID

Antigen Description

Component of the FACT complex, a general chromatin factor that acts to reorganize nucleosomes. The FACT complex is involved in multiple processes that require DNA as a template such as mRNA elongation, DNA replication and DNA repair. During transcription elongation the FACT complex acts as a histone chaperone that both destabilizes and restores nucleosomal structure. It facilitates the passage of RNA polymerase II and transcription by promoting the dissociation of one histone H2A-H2B dimer from the nucleosome, then subsequently promotes the reestablishment of the nucleosome following the passage of RNA polymerase II. The FACT complex is probably also involved in phosphorylation of Ser-392 of p53/TP53 via its association with CK2 (casein kinase II). Also involved in vitamin D-coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR-mediated transrepression of the CYP27B1 gene.

Pathway

Disease; Formation of HIV-1 elongation complex containing HIV-1 Tat; Formation of HIV-1 elongation complex in the absence of HIV-1 Tat; Formation of RNA Pol II elongation complex; Gene Expression; HIV Infection; HIV Life Cycle